» Articles » PMID: 37226733

Quartet of APOCs and the Different Roles They Play in Diabetes

Overview
Date 2023 May 25
PMID 37226733
Authors
Affiliations
Soon will be listed here.
Abstract

APOA1 and APOB are the structural proteins of high-density lipoprotein and APOB-containing lipoproteins, such as low-density lipoprotein and very low-density lipoprotein, respectively. The 4 smaller APOCs (APOC1, APOC2, APOC3, and APOC4) are exchangeable apolipoproteins; they are readily transferred among high-density lipoproteins and APOB-containing lipoproteins. The APOCs regulate plasma triglyceride and cholesterol levels by modulating substrate availability and activities of enzymes interacting with lipoproteins and by interfering with APOB-containing lipoprotein uptake through hepatic receptors. Of the 4 APOCs, APOC3 has been best studied in relation to diabetes. Elevated serum APOC3 levels predict incident cardiovascular disease and progression of kidney disease in people with type 1 diabetes. Insulin suppresses APOC3 levels, and accordingly, elevated APOC3 levels associate with insulin deficiency and insulin resistance. Mechanistic studies in a mouse model of type 1 diabetes have demonstrated that APOC3 acts in the causal pathway of diabetes-accelerated atherosclerosis. The mechanism is likely due to the ability of APOC3 to slow the clearance of triglyceride-rich lipoproteins and their remnants, thereby causing an increased accumulation of atherogenic lipoprotein remnants in lesions of atherosclerosis. Less is known about the roles of APOC1, APOC2, and APOC4 in diabetes.

Citing Articles

Multifaceted Role of Apolipoprotein C3 in Cardiovascular Disease Risk and Metabolic Disorder in Diabetes.

Pan B, Chen C, Chen F, Shen M Int J Mol Sci. 2024; 25(23.

PMID: 39684468 PMC: 11641554. DOI: 10.3390/ijms252312759.


Proteomic and Lipidomic Plasma Evaluations Reveal Biomarkers for Domoic Acid Toxicosis in California Sea Lions.

Solosky A, Claudio I, Chappel J, Kirkwood-Donelson K, Janech M, Bland A J Proteome Res. 2024; 23(12):5577-5585.

PMID: 39582169 PMC: 11752080. DOI: 10.1021/acs.jproteome.4c00820.


Macromolecular Interactions of Lipoprotein Lipase (LPL).

Wheless A, Gunn K, Neher S Subcell Biochem. 2024; 104:139-179.

PMID: 38963487 DOI: 10.1007/978-3-031-58843-3_8.


Elevated apolipoprotein C3 augments diabetic kidney disease and associated atherosclerosis in type 2 diabetes.

Cervantes J, Koska J, Kramer F, Akilesh S, Alpers C, Mullick A JCI Insight. 2024; 9(12).

PMID: 38743496 PMC: 11383354. DOI: 10.1172/jci.insight.177268.


Closing the gaps in patient management of dyslipidemia: stepping into cardiovascular precision diagnostics with apolipoprotein profiling.

Reijnders E, van der Laarse A, Ruhaak L, Cobbaert C Clin Proteomics. 2024; 21(1):19.

PMID: 38429638 PMC: 10908091. DOI: 10.1186/s12014-024-09465-w.


References
1.
Holmberg R, Refai E, Hoog A, Crooke R, Graham M, Olivecrona G . Lowering apolipoprotein CIII delays onset of type 1 diabetes. Proc Natl Acad Sci U S A. 2011; 108(26):10685-9. PMC: 3127896. DOI: 10.1073/pnas.1019553108. View

2.
GABOR J, Spain M, Kalant N . Composition of serum very-low-density and high-density lipoproteins in diabetes. Clin Chem. 1980; 26(9):1261-5. View

3.
Shimizu-Albergine M, Basu D, Kanter J, Kramer F, Kothari V, Barnhart S . CREBH normalizes dyslipidemia and halts atherosclerosis in diabetes by decreasing circulating remnant lipoproteins. J Clin Invest. 2021; 131(22). PMC: 8592537. DOI: 10.1172/JCI153285. View

4.
MacRaild C, Howlett G, Gooley P . The structure and interactions of human apolipoprotein C-II in dodecyl phosphocholine. Biochemistry. 2004; 43(25):8084-93. DOI: 10.1021/bi049817l. View

5.
Shachter N, Ebara T, Ramakrishnan R, Steiner G, Breslow J, Ginsberg H . Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl. J Clin Invest. 1996; 98(3):846-55. PMC: 507495. DOI: 10.1172/JCI118857. View